The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Open accessAbstract
BACKGROUND: Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death from melanoma) among patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm). The value of completion lymph-node dissection for patients with sentinel-node metastases is not clear. METHODS: In an international trial, we randomly assigned patients with sentinel-node metastases detected by means of standard pathological assessment or a multimarker molecular assay to immediate completion lymph-node dissection (dissection group) or nodal observation with ultrasonography (observation group). The primary end point was melanoma-specific survival. Secondary end points included disease-free survival and the cumulative rate of nonsentinel-node metastasis. RESULTS: Immediate completion lymph-node dissection was not associated with increased melanoma-specific survival among 1934 patients with data that could be evaluated in an intention-to-treat analysis or among 1755 patients in the per-protocol analysis. In the per-protocol analysis, the mean (±SE) 3-year rate of melanoma-specific survival was similar in the dissection group and the observation group (86±1.3% and 86±1.2%, respectively; P=0.42 by the log-rank test) at a median follow-up of 43 months. The rate of disease-free survival was slightly higher in the dissection group than in the observation group (68±1.7% and 63±1.7%, respectively; P=0.05 by the log-rank test) at 3 years, based on an increased rate of disease control in the regional nodes at 3 years (92±1.0% vs. 77±1.5%; P<0.001 by the log-rank test); these results must be interpreted with caution. Nonsentinel-node metastases, identified in 11.5% of the patients in the dissection group, were a strong, independent prognostic factor for recurrence (hazard ratio, 1.78; P=0.005). Lymphedema was observed in 24.1% of the patients in the dissection group and in 6.3% of those in the observation group. CONCLUSIONS: Immediate completion lymph-node dissection increased the rate of regional disease control and provided prognostic information but did not increase melanoma-specific survival among patients with melanoma and sentinel-node metastases. (Funded by the National Cancer Institute and others; MSLT-II ClinicalTrials.gov number, NCT00297895 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sentinel-Node Biopsy or Nodal Observation in Melanoma
Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Elashoff, R., Essner, R., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., Karakousis, C. P., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060992 · Cited by 1,824
Self-citationFinal Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., Karakousis, C. P., Puleo, C. A., Coventry, B. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310460 · Cited by 1,484
Self-citationMorton, D. L., Cochran, A. J., Thompson, J. F., Elashoff, R., Essner, R., Glass, E. C., Mozzillo, N., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000181092.50141.fa · Cited by 715
Self-citationLeiter, U., Stadler, R., Mauch, C., Hohenberger, W., Brockmeyer, N., Berking, C., Sunderkötter, C., Kaatz, M., Schulte, K.-W., Lehmann, P., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00141-8 · Cited by 707
Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L., Grob, J.-J., Malvehy, J., Newton-Bishop, J., Stratigos, A. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.005 · Cited by 605
Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Spatz, A., Grob, J.-J., Malvehy, J., Newton-Bishop, J., Stratigos, A., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.013 · Cited by 229
NCCN Guidelines Insights: Melanoma, Version 3.2016
Coit, D. G., Thompson, J. A., Algazi, A. P., Andtbacka, R. H. I., Bichakjian, C. K., Carson, W. E., Daniels, G. A., DiMaio, D. J., Fields, R. C., Fleming, M. D., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0101 · Cited by 102
Self-citationA method to estimate treatment efficacy among latent subgroups of a randomized clinical trial
Altstein, L. L., Li, G., & Elashoff, R. M. (2010) · Statistics in Medicine · doi:10.1002/sim.4131 · Cited by 43
Self-citation
Cited by
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Schadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., Stang, A., Roesch, A., & Ugurel, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31559-9 · Cited by 1,488
Lymph protects metastasizing melanoma cells from ferroptosis
Ubellacker, J. M., Tasdogan, A., Ramesh, V., Shen, B., Mitchell, E. C., Martin-Sandoval, M. S., Gu, Z., McCormick, M. L., Durham, A. B., Spitz, D. R., et al. (2020) · Nature · doi:10.1038/s41586-020-2623-z · Cited by 896
Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00821-8 · Cited by 746
Self-citationGuidelines of care for the management of primary cutaneous melanoma
Swetter, S. M., Tsao, H., Bichakjian, C. K., Curiel-Lewandrowski, C., Elder, D. E., Gershenwald, J. E., Guild, V., Grant-Kels, J. M., Halpern, A. C., Johnson, T. M., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.08.055 · Cited by 727
Self-citationCutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R., & Keilholz, U. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz411 · Cited by 617
Self-citationKeung, E. Z., & Gershenwald, J. E. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1489246 · Cited by 593
Self-citationPereira, E. R., Kedrin, D., Seano, G., Gautier, O., Meijer, E. F. J., Jones, D., Chin, S.-M., Kitahara, S., Bouta, E. M., Chang, J., et al. (2018) · Science · doi:10.1126/science.aal3622 · Cited by 477
Biological functions of lymphatic vessels
Petrova, T. V., & Koh, G. Y. (2020) · Science · doi:10.1126/science.aax4063 · Cited by 457
Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond
Gershenwald, J. E., & Scolyer, R. A. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6513-7 · Cited by 452
Self-citationCutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Coit, D. G., Thompson, J. A., Albertini, M. R., Barker, C., Carson, W. E., Contreras, C., Daniels, G. A., DiMaio, D., Fields, R. C., Fleming, M. D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0018 · Cited by 436
Self-citationFluids and their mechanics in tumour transit: shaping metastasis
Follain, G., Herrmann, D., Harlepp, S., Hyenne, V., Osmani, N., Warren, S. C., Timpson, P., & Goetz, J. G. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0221-x · Cited by 412
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Kirkwood, J. M., Chiarion Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005493 · Cited by 408
Self-citationEggermont, A. M. M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00065-6 · Cited by 387
Self-citationRecent Advances in the Treatment of Melanoma
Curti, B. D., & Faries, M. B. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2034861 · Cited by 386
Self-citationLymph node colonization induces tumor-immune tolerance to promote distant metastasis
Reticker-Flynn, N. E., Zhang, W., Belk, J. A., Basto, P. A., Escalante, N. K., Pilarowski, G. O. W., Bejnood, A., Martins, M. M., Kenkel, J. A., Linde, I. L., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.019 · Cited by 385
Metastasis-Initiating Cells and Ecosystems
Massagué, J., & Ganesh, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0010 · Cited by 372
Swetter, S. M., Thompson, J. A., Albertini, M. R., Barker, C. A., Baumgartner, J., Boland, G., Chmielowski, B., DiMaio, D., Durham, A., Fields, R. C., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0018 · Cited by 340
Self-citationTreatment of Advanced Melanoma in 2020 and Beyond
Jenkins, R. W., & Fisher, D. E. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.943 · Cited by 339
Tumor-draining lymph nodes: At the crossroads of metastasis and immunity
du Bois, H., Heim, T. A., & Lund, A. W. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg3551 · Cited by 323
Wong, S. L., Faries, M. B., Kennedy, E. B., Agarwala, S. S., Akhurst, T. J., Ariyan, C., Balch, C. M., Berman, B. S., Cochran, A., Delman, K. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7724 · Cited by 284
Self-citationEuropean consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Basset-Seguin, N., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.018 · Cited by 283
Systemic Therapy for Melanoma: ASCO Guideline
Seth, R., Messersmith, H., Kaur, V., Kirkwood, J. M., Kudchadkar, R., McQuade, J. L., Provenzano, A., Swami, U., Weber, J., Alluri, K. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00198 · Cited by 265
Self-citationEcker, B. L., Kaur, A., Douglass, S. M., Webster, M. R., Almeida, F. V., Marino, G. E., Sinnamon, A. J., Neuwirth, M. G., Alicea, G. M., Ndoye, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0168 · Cited by 153
Self-citationHistone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes
Leslie, P. L., Chao, Y. L., Tsai, Y.-H., Ghosh, S. K., Porrello, A., Van Swearingen, A. E. D., Harrison, E. B., Cooley, B. C., Parker, J. S., Carey, L. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12222-5 · Cited by 80
Metadata
- Authors
- Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., Hoekstra, H. J., Moncrieff, M., Ingvar, C., Wouters, M. W. J. M., Sabel, M. S., Levine, E. A., Agnese, D., Henderson, M., Dummer, R., Rossi, C. R., Neves, R. I., Trocha, S. D., Wright, F., Byrd, D. R., Matter, M., Hsueh, E., MacKenzie-Ross, A., Johnson, D. B., Terheyden, P., Berger, A. C., Huston, T. L., Wayne, J. D., Smithers, B. M., Neuman, H. B., Schneebaum, S., Gershenwald, J. E., Ariyan, C. E., Desai, D. C., Jacobs, L., McMasters, K. M., Gesierich, A., Hersey, P., Bines, S. D., Kane, J. M., Barth, R. J., McKinnon, G., Farma, J. M., Schultz, E., Vidal-Sicart, S., Hoefer, R. A., Lewis, J. M., Scheri, R., Kelley, M. C., Nieweg, O. E., Noyes, R. D., Hoon, D. S. B., Wang, H.-J., Elashoff, D. A., & Elashoff, R. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-06-08
- Volume
- 376
- Issue
- 23
- Pages
- 2211-2222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2624147378
- Cited by
- 1,414
- References
- 8
- FWCI
- 65.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.